Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

infection (CDI) has been recognized as a leading cause of healthcare-associated infections and a considerable threat to public health globally. Increasing evidence suggests that the gut microbiota plays a key role in the pathogenesis of CDI. The taxonomic composition and functional capacity of the gut microbiota associated with CDI have not been studied systematically. Here, we performed a comprehensive shotgun metagenomic sequencing in a well-characterized human cohort to reveal distinct patterns of gut microbiota and potential functional features associated with CDI. Fecal samples were collected from 104 inpatients, including : (1) patients with clinically significant diarrhea and positive nucleic acid amplification testing (NAAT) and received CDI treatment (CDI,  = 47); (2) patients with positive stool NAAT but without diarrhea (Carrier,  = 17); (3) patients with negative stool NAAT but with diarrhea (Diarrhea,  = 14); and (4) patients with negative stool NAAT and without diarrhea (Control,  = 26). Downstream statistical analyses (including alpha and beta diversity analysis, differential abundance analysis, correlation network analysis, and potential functional analysis) were then performed. The gut microbiota in the Control group showed higher Chao1 index ( < 0.05), while Shannon index at KEGG module level was higher in CDI than in Carrier and Control ( < 0.05). Beta diversity for species composition differed significantly between CDI vs Carrier/Control cohorts ( < 0.05). Microbial Linear discriminant analysis Effect Size and ANCOM analysis both identified 8 species (, and etc.) were enriched in CDI, was enriched in Diarrhea, , , and were enriched in Control (LDA >3.0, adjusted  < 0.05). Correlation network complexity was higher in CDI with more negative correlations than in other three cohorts. Modules involved in iron complex transport system (M00240) was enriched in CDI, ABC-2 type transport system (M00254), aminoacyl-tRNA biosynthesis (M00359), histidine biosynthesis (M00026) and inosine monophosphate biosynthesis (M00048) were enriched in Carrier, ribosome (M00178 and M00179) was enriched in Diarrhea, fluoroquinolone resistance (M00729) and aminoacyl-tRNA biosynthesis (M00360) were enriched in Control (LDA > 2.5, adjusted  < 0.05). Resistance functions of acriflavine and glycylcycline were enriched in CDI, while resistance function of bacitracin was enriched in Carrier (LDA > 3.0, adjusted  < 0.05), and the contributions of phylum and species to resistance functions differed among the four groups. Our results reveal alterations of gut microbiota composition and potential functions among four groups of differential colonization/infection status of . These findings support the potential roles of gut microbiota and their potential functions in the pathogenesis of CDI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080279PMC
http://dx.doi.org/10.1080/19490976.2025.2505269DOI Listing

Publication Analysis

Top Keywords

gut microbiota
20
stool naat
12
naat diarrhea
12
distinct patterns
8
patterns gut
8
infection cdi
8
associated cdi
8
potential functional
8
patients negative
8
negative stool
8

Similar Publications

EVOLVING TRENDS AND EMERGING THEMES IN GUT MICROBIOTA RESEARCH: A COMPREHENSIVE BIBLIOMETRIC ANALYSIS (2015-2024).

Arq Gastroenterol

September 2025

The Japanese Society of Internal Medicine, Editorial Department, Tokyo, Japan.

Background: This study aims to analyze research trends and emerging insights into gut microbiota studies from 2015 to 2024 through bibliometric analysis techniques. By examining bibliographic data from the Web of Science (WoS) Core Collection, it seeks to identify key research topics, evolving themes, and significant shifts in gut microbiota research. The study employs co-occurrence analysis, principal component analysis (PCA), and burst detection analysis to uncover latent patterns and the development trajectory of this rapidly expanding field.

View Article and Find Full Text PDF

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

J Crohns Colitis

September 2025

Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Marseille, France.

Background And Aims: While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification.

Methods: We conducted a retrospective study in 25 centers including all patients with active ulcerative colitis (UC) or Crohn's disease (CD) (defined by PRO2), and incomplete or loss of response to SC VDZ 108mg EOW when the drug was intensified.

View Article and Find Full Text PDF

Background: The brain-gut-microbiome (BGM) axis is a communication network through which the brain and gastrointestinal microbiota interact via neural, hormonal, immune, and gene expression mechanisms. Gut microbiota dysbiosis is thought to contribute to neurocognitive disorders, including perioperative neurocognitive disorder (PND), and to various metabolic abnormalities. Recently, we reported that sevoflurane induces neurocognitive deficits in exposed rats as well as their future offspring, with male offspring being particularly affected (intergenerational PND).

View Article and Find Full Text PDF

From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.

Curr Atheroscler Rep

September 2025

Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.

Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.

Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.

View Article and Find Full Text PDF